Clinical trial
A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144…
NCT00384774 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00384774 |
|---|---|
| Title | A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine |
| Official title | A Placebo-Controlled, Group Sequential, Adaptive Treatment Assignment Study of Intravenous COL-144 (LY573144) in the Acute Treatment of Migraine |
| Lead sponsor | Eli Lilly and Company, Industry |
| Collaborators | CoLucid Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Migraine |
| Intervention type | Drug |
| Interventions | Lasmiditan, Placebo |
| Enrollment | 130 |
| Start date | Nov 1, 2006 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Oct 6, 2006 |
| Last update posted | Dec 2, 2019 |
| Countries | Finland, Germany, Netherlands |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: